FDA Approves Gilead’s Next-Generation ‘Breakthrough’ Hepatitis C Drug

December 6, 2013
Drugs Commercial Operations Regulatory Affairs Submissions and Approvals
The FDA has approved Gilead’s hepatitis C drug sofosbuvir, which received a unanimous recommendation from agency advisors.

To View This Article:

Login

Subscribe To FDAnews

Upcoming Events

Featured Products

Featured Stories

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Learn More